It won't be easy for the company to bounce back.Being a highly innovative company isn't a sufficient condition for success in the biotech industry. Bluebird Bio (BLUE), a small-cap gene-editing specialist, is a good example of this. Though the company has developed groundbreaking therapies, the stock has significantly lagged the market in recent years. Still, if Bluebird Bio can turn things around, the company could deliver explosive returns to investors who initiate a position today. Is Bluebird Bio worth ...